GlassScriptPhysician profile
David R Sprouse
NPI 1487761326
$2,846.99
in general payments reported to CMS, 2019-2025
30 companies · $575 in 2025
The $575 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $181 · 2021: $224 · 2022: $340 · 2023: $723 · 2024: $625 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $507.19 | 2023-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $320.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $289.55 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $234.33 | 2020-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $223.80 | 2022-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $204.09 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $186.70 | 2020-2025 | Gardasil 9, Capvaxive, Vaqta |
| Amgen INC. | $154.94 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Exact Sciences Corporation | $95.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Globus Medical, INC. | $80.78 | 2025 | Senza |
| Amarin Pharma, INC. | $53.93 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $45.92 | 2019-2023 | Spravato |
| Inspire Medical Systems, INC. | $44.29 | 2025 | Inspire |
| Nevro Corp. | $39.91 | 2024 | Senza |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $35.30 | 2022-2023 | |
| Pfizer INC. | $32.85 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.40 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $23.70 | 2021 | |
| Abbott Laboratories | $22.50 | 2024 | Proclaim |
| Sanofi Pasteur INC. | $22.32 | 2023 | |
| Ironshore Pharmaceuticals INC. | $20.78 | 2019 | |
| Axsome Therapeutics, INC. | $20.39 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.02 | 2022 | |
| Almatica Pharma LLC | $15.49 | 2022 | |
| Shire North American Group INC | $13.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sprouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.